TheraMe! High impact

News

20.2.2025

11.06.2026

bla bla bla

Our CTO, Hana Samet, will take part in an expert roundtable discussion at the Valorization Award, organized by Knowledge Transfer UNIL-CHUV

01.11.2025

We have finalized our first fully integrated alpha prototype for microfluidic drug testing. This major milestone brings us closer to delivering a scalable IVD product for patient-specific therapy testing

TheraMe! has obtained ISO 13485 certification for design and development of its products. This certification validates our commitment to the highest international standards in medical device quality and risk management

23.01.2025

Press release: CSEM and TheraMe! collaboration revolutionizing cancer therapy with personalized drug screening technology 

10.12.2024

It was a privilege to pitch at the EPFL Investor Day event, where we gained valuable insights, built strategic relationships

01.11.2024

We are excited to welcome Mehmet Sehir to our team as a Bioinformatician, bringing his skills in NGS data analysis and algorithm development

25.04.2024

TheraMe! was honored to be one of the 20 startups selected to pitch the Startup Champions Seed Night, showcasing our innovative solutions to over 500 attendee

24.01.2024

TheraMe! is awarded an Innosuisse grant for the development of an industry prototype in collaboration with CSEM

15.12.2023

TheraMe! unveils an enhanced prototype for streamlined IVD screens

11.05.2023

TheraMe! wins audience award at AGORA BioInnovation day

14.04.2022

TheraMe! selected among 10 finalists in the Health & Nutrition vertical of the Venture 2022 competition

01.11.2021

EPFL host lab receives prestigious PHRT grant for TheraMe! groundbreaking cancer therapy project

01.11.2025

Dr. Emmanuel Delamarche has joined TheraMe! as an Industry Advisor. A leading expert in microfluidics and diagnostics, he brings decades of experience in translating innovation into real-world applications

16.08.2021

Kick-off for the Innovative "TheraMe!" Innosuisse project

15.04.2026

Raffaele M. Iannuzzi joins us as a Bioinformatician Penelope Stefanelli joins as a Clinical Development Assistant

15.10.2025

We welcome three new team members to TheraMe!. Their expertise will strengthen our innovation and help drive the next stage of growth

10.06.2026

Meet us at Swiss Medtech Day, where Prof. Christoph Merten and our CTO Hana Samet will be speaking in a Deep Dive Session

Publications

Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. Nat Commun 13, 4450 (2022). Mathur, L., Szalai, B., Du, N.H. et al.

Technological and computational advances driving high-throughput oncology. Trends Cell Biol. 2022 Nov;32(11):947-961. Kolmar L, Autour A, Ma X, Vergier B, Eduati F, Merten CA.

A microfluidic Braille valve platform for on-demand production, combinatorial screening and sorting of chemically distinct droplets. Utharala, R*., Grab, A*., Vafaizadeh, V*. et al. Nat Protoc (2022), * Contributed equally.

Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, Saez-Rodriguez J. Molecular Systems Biology (16)e8664: 1-13, 2020

Microfluidics as an Enabling Technology for Personalized Cancer Therapy. Mathur L*, Ballinger M*, Utharala R*, Merten CA. Small. E1904321: 1-18, 2019

A microfluidics platform for combinatorial drug screening on cancer biopsies. Eduati F*, Utharala R*, Madhavan D, Neumann UP, Longerich T, Cramer T, Saez-Rodriguez J, Merten CA. Nature Communications. 9(1):2434: 1-13, 2018